Scandurra Giuseppa, Sambataro Daniela, Gebbia Vittorio, Piazza Dario, Valerio Maria Rosaria
Medical Oncology Unit, Ospedale Cannizzaro, Catania, Italy.
Chair of Medical Oncology, School of Medicine, University of Enna Kore, Enna, Italy.
J Cancer Educ. 2024 Oct 19. doi: 10.1007/s13187-024-02524-8.
Herpes zoster (HZ) virus reactivation is a significant medical problem among immunocompromised patients, especially considering its potential complications. Although the recombinant HZ vaccine has demonstrated > 90% efficacy against HZ in adults, its use is not as frequent as needed in daily oncology practice due to several barriers, including oncologists' knowledge, patients' willingness, and organizational issues. A web-based survey was sent to 139 oncologists treating solid tumors concerning their knowledge and attitudes toward the adjuvanted gE-based recombinant HZ vaccination. The survey included questions regarding the characteristics of medical oncologists participating, such as the type of hospital, main field of expertise, percent of work with patients, awareness of the HZ risk in cancer patients, knowledge of scientific data and scientific societies guidelines on HZ vaccination, familiarity with vaccinations, frequency of HZ detection in clinical practice, barriers, and challenges toward vaccine administration. Fifty-four physicians (46%; 95% CI 0.2918 to 0.5069) responded to all the questions. The main reason for non-response was the lack of time due to the overwhelming burden of assistance. When the survey was launched, 31 participants reported good knowledge of scientific and clinical data of HZ vaccines, 10% none, and 36 were aware of guidelines. Reported barriers included knowledge of the problem, patients' willingness, and organizational issues. Surveying medical oncologists on the adjuvanted gE-based recombinant HZ vaccination provides essential insights into their knowledge, attitudes, and practices regarding vaccination for cancer patients. These data suggest that continuing medical education is necessary to implement HZ vaccination prescription among oncologists.
带状疱疹（HZ）病毒再激活在免疫功能低下的患者中是一个重大的医学问题，尤其是考虑到其潜在的并发症。尽管重组HZ疫苗在成人中对HZ的疗效已证明超过90%，但由于包括肿瘤学家的认知、患者的意愿以及组织问题等多个障碍，其在日常肿瘤学实践中的使用频率并未达到所需水平。一项基于网络的调查被发送给139名治疗实体瘤的肿瘤学家，询问他们对基于gE佐剂的重组HZ疫苗接种的知识和态度。该调查包括有关参与调查的医学肿瘤学家特征的问题，如医院类型、主要专业领域、与患者工作的百分比、对癌症患者HZ风险的认识、对HZ疫苗接种的科学数据和科学学会指南的了解、对疫苗接种的熟悉程度、临床实践中HZ的检测频率、疫苗接种的障碍和挑战。54名医生（46%；95%可信区间0.2918至0.5069）回答了所有问题。未回复的主要原因是由于援助负担过重而缺乏时间。在调查启动时，31名参与者表示对HZ疫苗的科学和临床数据有良好的了解，10%表示一无所知，36名知晓指南。报告的障碍包括对问题的认识、患者的意愿和组织问题。对医学肿瘤学家进行基于gE佐剂的重组HZ疫苗接种调查，能深入了解他们对癌症患者疫苗接种的知识、态度和实践。这些数据表明，持续医学教育对于在肿瘤学家中实施HZ疫苗接种处方是必要的。
